Video: MASLD Nomenclature: Why the Change?
—Sobia Laique, MD, of Cleveland Clinic, discusses the name change from NAFLD to MASLD and how the re-classification helps in the clinical management of patients. (3:26)
Published:
.jpg)
These data confirm that lean patients with MASH may be at greater risk of poor health outcomes than non-lean patients with MASH.
Data on clinical outcomes in MASLD are lacking. This study鈥檚 goal was to provide a comprehensive meta-analysis of the longitudinal outcomes associated with MASLD.
.jpg)
Serum lipid-soluble micronutrients, such as 25(OH)D and carotenoids, may be protective in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), whereas tocopherols may be associated with pathology, according to this report.
.jpg)
Christos S. Mantzoros, MD, DSc, PhD, professor of medicine at Harvard Medical School and Boston University, answers our questions about changes in the way we approach steatotic liver disease, formerly known as fatty liver disease.
Investigators reported on the clinical utility of several non-invasive screening methods to reduce the burden of invasive liver tissue sampling in patients at risk of MASH.
Patients over age 50 with type 2 diabetes are at particular risk for metabolic dysfunction-associated steatohepatitis, according to the results of this study.